Results 221 to 230 of about 755,200 (268)
Some of the next articles are maybe not open access.

Tumor vasculature-targeting nanomedicines

Acta Biomaterialia, 2021
Uncontrolled tumor growth and subsequent distant metastasis are highly dependent on an adequate nutrient supply from tumor blood vessels, which have relatively different pathophysiological characteristics from those of normal vasculature. Obviously, strategies targeting tumor vasculature, such as anti-angiogenic drugs and vascular disrupting agents ...
Ying, Zhang, Jingni, He
openaire   +2 more sources

CD81 as a tumor target

Biochemical Society Transactions, 2017
CD81 participates in a variety of important cellular processes such as membrane organization, protein trafficking, cellular fusion and cell–cell interactions. In the immune system, CD81 regulates immune synapse, receptor clustering and signaling; it also mediates adaptive and innate immune suppression.
Felipe, Vences-Catalán   +5 more
openaire   +2 more sources

Targeting tumor cells

Current Opinion in Cell Biology, 2003
Several recent scientific and technical developments have made it possible to postulate the use of the 'magic bullet' concept; that is, the identification of specific antigens present on tumor cells that can be targeted either by therapeutic antibodies or by small molecules.
Pantea, Houshmand, Albert, Zlotnik
openaire   +2 more sources

Targeting Macrophages for Tumor Therapy

The AAPS Journal, 2023
Macrophages, as one of the most abundant tumor-infiltrating cells, play an important role in tumor development and metastasis. The frequency and polarization of tumor-associated macrophages (TAMs) correlate with disease progression, tumor metastasis, and resistance to various treatments.
Yixin, Wang, Allie, Barrett, Quanyin, Hu
openaire   +2 more sources

Targeting Tumor Angiogenesis

Seminars in Oncology, 2009
Our understanding of the process of tumor angiogenesis has changed significantly since the late 1970s, when vascular endothelial growth factor (VEGF) was first identified as vascular permeability factor and later found to be the major mediator of physiologic and pathologic angiogenesis.
Puja, Gaur   +3 more
openaire   +2 more sources

Targeting Tumor Angiogenesis

2013
Four decades after the seminal work of Judah Folkman, in 1971, cancer therapies based on the suppression of neo-angiogenesis (Folkman, N Engl J Med 285:1182–1186, 1971) are becoming a reality (Verheul et al., Clin Cancer Res 14(11):3589–3597, 2008).
STAIBANO, STEFANIA   +1 more
openaire   +2 more sources

Colloidal Systems for Tumor Targeting

Hybridoma, 1997
The potential and limitations of targeted delivery of anticancer agents with colloidal particulate carriers is the subject of this contribution. Because over the years liposomes have gained the most attention as carrier system in the category of colloidal carrier systems, this paper focuses on the utility of the liposomal system for tumor targeting. It
Storm, G., Crommelin, D.J.A.
openaire   +3 more sources

Targeting Pituitary Tumors

Hormone Research in Paediatrics, 2007
<i>Background:</i> Pituitary tumors are common and usually grow insidiously over many years. Rarely fatal, treatment still requires multiple cytoreductive surgeries and/or radiation therapy with its attendant side effects. As a disease process of regulatory pathways, pituitary tumors offer numerous potential therapeutic targets, and many ...
openaire   +2 more sources

Combination Vascular Targeted and Tumor Targeted Radioimmunotherapy

Cancer Biotherapy and Radiopharmaceuticals, 1999
Rat MAb 201B, which binds to murine thrombomodulin, can deliver up to 50% of the injected dose of attached radioisotopes to the lung vascular endothelium. We have shown previously that intravenous injection of about 30 microCi of 213Bi-MAb 201B, which delivers about 15 Gy of alpha irradiation to the lung, is capable of eradicating small lung colonies ...
S J, Kennel   +5 more
openaire   +2 more sources

Tumor-Associated Macrophages as Targets for Tumor Immunotherapy

Immunotherapy, 2008
Restoration of one of the major physiological functions of the body's immune response, the rejection of malignant cells, is a promising yet challenging task for cancer therapy. Prinicipally, immunotherapeutic approaches make use of cells of the adaptive immune system, since antigen-based tumor rejection might be the most specific approach.
Andreas, Weigert   +2 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy